Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.92
+0.02 (0.12%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 114.54 | 105.9 | -56.42 | -55.19 | -92.82 | -265.07 |
Depreciation & Amortization | 5.7 | 5.64 | 6.12 | 6.15 | 7.71 | 8.59 |
Stock-Based Compensation | 18.1 | 18.48 | 21.39 | 25.37 | 39.73 | 62.06 |
Other Adjustments | -13.96 | -11.94 | -2.99 | 5.01 | 0.61 | -1.8 |
Change in Receivables | 49.77 | -27.1 | -0.97 | -0.69 | -2.72 | 1.8 |
Changes in Accounts Payable | -1.31 | 0.33 | 0.75 | 0.01 | -1.61 | -3.53 |
Changes in Accrued Expenses | 0.66 | 4.01 | 1.47 | -7.1 | -15.33 | -37.23 |
Changes in Income Taxes Payable | 10.67 | 10.48 | 9.91 | 1.1 | 63.95 | -0.19 |
Changes in Unearned Revenue | - | - | - | -0.22 | -0.19 | -11.46 |
Changes in Other Operating Activities | -9.62 | 132.75 | 9.2 | -1.45 | -186.31 | 38.98 |
Operating Cash Flow | 268.78 | 238.54 | -11.54 | -27 | -186.99 | -207.86 |
Operating Cash Flow Growth | 726.36% | - | - | - | - | - |
Capital Expenditures | - | -0.04 | -0.33 | -2.49 | -0.57 | -3.41 |
Sale of Property, Plant & Equipment | - | - | - | 1.51 | 1.87 | 0.01 |
Purchases of Investments | -289.66 | -248.22 | -143.04 | -134.53 | -103.15 | -158.31 |
Proceeds from Sale of Investments | 206.38 | 142.98 | 155.65 | 102.81 | 158.02 | 286.2 |
Proceeds from Business Divestments | - | - | - | - | 2.71 | - |
Other Investing Activities | - | - | - | - | 1,095 | - |
Investing Cash Flow | -83.32 | -105.28 | 12.28 | -32.7 | 1,154 | 124.49 |
Long-Term Debt Issued | - | - | - | - | 24.46 | - |
Long-Term Debt Repaid | - | - | - | - | -631.6 | -10.73 |
Net Long-Term Debt Issued (Repaid) | - | - | - | - | -607.14 | -10.73 |
Issuance of Common Stock | -19.98 | 0.79 | 0.61 | 0.62 | 0.8 | 111.65 |
Repurchase of Common Stock | -8.98 | -4.03 | -3.1 | -199.55 | -132.28 | -9.06 |
Net Common Stock Issued (Repurchased) | -28.96 | -3.25 | -2.5 | -198.93 | -131.48 | 102.59 |
Other Financing Activities | - | - | - | - | -20.19 | - |
Financing Cash Flow | -7.97 | -3.25 | -2.5 | -198.93 | -758.81 | 91.86 |
Net Cash Flow | 177.49 | 130.01 | -1.75 | -258.63 | 208.21 | 8.5 |
Free Cash Flow | 268.78 | 238.5 | -11.87 | -29.49 | -187.56 | -211.26 |
Free Cash Flow Growth | 726.36% | - | - | - | - | - |
FCF Margin | 244.85% | 221.93% | -18.43% | -51.35% | -365.29% | -381.96% |
Free Cash Flow Per Share | 5.18 | 4.63 | -0.24 | -0.53 | -2.55 | -3.04 |
Levered Free Cash Flow | 1.16 | 282.42 | -17.5 | -59.18 | 132.64 | -218.41 |
Unlevered Free Cash Flow | 5.77 | 149.57 | -19.84 | -60.02 | -224.32 | -265.89 |